{"id":36376,"date":"2026-11-02T17:34:00","date_gmt":"2026-11-02T12:04:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=36376"},"modified":"2026-11-02T16:35:23","modified_gmt":"2026-11-02T11:05:23","slug":"ultomiris-for-igan-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/ultomiris-for-igan-treatment","title":{"rendered":"AstraZeneca\u2019s ULTOMIRIS: The First C5 Inhibitor Enters the Race to Tame Proteinuria in IgA Nephropathy"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6ae884af87083\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6ae884af87083\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/ultomiris-for-igan-treatment\/#IgA_Nephropathy_A_Quiet_Disease_with_a_Heavy_Burden\" >IgA Nephropathy: A Quiet Disease with a Heavy Burden<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/ultomiris-for-igan-treatment\/#ULTOMIRIS_MoA_Why_Blocking_C5_Makes_Sense_in_IgAN\" >ULTOMIRIS MoA: Why Blocking C5 Makes Sense in IgAN<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/ultomiris-for-igan-treatment\/#The_New_Landscape_of_IgA_Nephropathy_Treatments\" >The New Landscape of IgA Nephropathy Treatments<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/ultomiris-for-igan-treatment\/#C5_vs_Factor_B_Two_Complement_Strategies_Two_Different_Targets\" >C5 vs. Factor B: Two Complement Strategies, Two Different Targets<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/ultomiris-for-igan-treatment\/#Conclusion\" >Conclusion&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<p><strong><em>Summary<\/em><\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>FDA granted accelerated approval to AstraZeneca\u2019s ULTOMIRIS on October 21, 2026, to reduce proteinuria in adults with primary IgAN at risk of progression.<\/em><\/li>\n\n\n\n<li><em>It is the fifth US rare disease indication for ULTOMIRIS and the first and only C5 inhibitor approved for this use.<\/em><\/li>\n\n\n\n<li><em>In I CAN, 24-hour UPCR fell 46.6% with ULTOMIRIS vs 5.6% with placebo at Week 34 (43.4% placebo-adjusted), with effects seen as early as Week 10.<\/em><\/li>\n\n\n\n<li><em>The ULTOMIRIS MoA is terminal complement (C5) inhibition, distinct from Fabhalta&#8217;s Factor B target.<\/em><\/li>\n\n\n\n<li><em>Continued approval depends on Week 106 eGFR data; no comparative efficacy claims versus other IgA nephropathy medications can be drawn from current evidence.<\/em><\/li>\n\n\n\n<li><em>The approval positions ULTOMIRIS to compete in an increasingly crowded market alongside established treatments such as Calliditas Therapeutics\u2019 TARPEYO, Travere Therapeutics\u2019 FILSPARI, and Novartis\u2019 FABHALTA, while several additional investigational therapies from competing pharmaceutical companies remain in development.<\/em><\/li>\n<\/ul>\n\n\n\n<p>For years, people living with IgA nephropathy (IgAN) had very little to hold onto beyond blood pressure control and supportive care. In 2026, that picture looks dramatically different. On October 21, 2026, the US Food and Drug Administration (FDA) granted accelerated approval to <strong>AstraZeneca&#8217;s ULTOMIRIS<\/strong> (ravulizumab-cwvz) to reduce proteinuria in adults with primary IgAN who are at risk of disease progression. It is the latest and one of the most closely watched entries in a fast-moving category, and it is the first time a <a href=\"https:\/\/www.delveinsight.com\/report-store\/c5-complement-inhibitor-market-forecast\">C5 complement inhibitor<\/a> has been cleared for this use.<\/p>\n\n\n\n<p>The FDA&#8217;s decision follows a Priority Review and rests on a prespecified interim analysis of the <strong>global Phase III I CAN trial<\/strong>. The indication is for reducing proteinuria in adults with primary IgAN who are at risk of disease progression, and it was granted under the accelerated approval pathway, which allows the agency to clear a therapy based on a surrogate endpoint that is reasonably likely to predict clinical benefit. In IgAN, that surrogate is proteinuria.<\/p>\n\n\n\n<p>Three key factors make this approval particularly noteworthy. First, IgAN becomes the fifth rare disease indication for ULTOMIRIS in the United States, expanding its established presence in complement-mediated conditions, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Second, ULTOMIRIS is the first and only C5 complement inhibitor approved to reduce proteinuria in patients with IgAN, marking an important milestone in the treatment landscape. Third, the approval was granted under the FDA\u2019s accelerated approval pathway, meaning that whether ULTOMIRIS can slow the decline in kidney function in patients with IgAN has not yet been established.&nbsp;<\/p>\n\n\n\n<p>Continued approval may depend on confirmation of clinical benefit through the ongoing I CAN trial, which will evaluate the change in estimated glomerular filtration rate (eGFR) at Week 106 as its primary endpoint. This distinction is important because accelerated approval represents an initial regulatory milestone rather than definitive confirmation of long-term clinical benefit. The Week 106 eGFR results are expected to support consideration of traditional approval and will be crucial in determining whether the reduction in proteinuria achieved with ULTOMIRIS translates into the preservation of kidney function over time.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-iga-nephropathy-a-quiet-disease-with-a-heavy-burden\"><span class=\"ez-toc-section\" id=\"IgA_Nephropathy_A_Quiet_Disease_with_a_Heavy_Burden\"><\/span><strong>IgA Nephropathy: A Quiet Disease with a Heavy Burden<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>IgAN, also known as Berger&#8217;s disease, is a rare, inflammatory kidney disease. It begins with the production of abnormal IgA antibodies that accumulate in the glomeruli, the tiny filters of the kidney. That deposition triggers inflammation and injury, allowing protein and sometimes blood to leak into the urine. More than <strong>200,000<\/strong> people in the United States are estimated to live with IgAN. According to DelveInsight\u2019s estimates, in 2025, the US reported nearly <strong>135,000<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/iga-nephropathy-igan-market\">diagnosed prevalent cases of IgAN<\/a>.<\/p>\n\n\n\n<p>What makes IgAN so challenging is how quietly it can progress. Many patients are diagnosed in early adulthood, often after a routine urinalysis or an episode of visible blood in the urine. Symptoms can be absent for years. Yet persistent proteinuria is a recognized signal of ongoing kidney injury and a marker of heightened risk, and a meaningful share of patients go on to develop chronic kidney disease and, eventually, end-stage kidney disease (ESKD) requiring dialysis or transplantation. For a disease that so often strikes people in their prime working and family-building years, the long-term personal and economic burden is substantial.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"521\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/IgA-Nephropathy-Patient-Pool-Analysis-1024x521.webp\" alt=\"IgA-Nephropathy-Patient-Pool-Analysis\" class=\"wp-image-36382\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/IgA-Nephropathy-Patient-Pool-Analysis-1024x521.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/IgA-Nephropathy-Patient-Pool-Analysis-300x153.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/IgA-Nephropathy-Patient-Pool-Analysis-150x76.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/IgA-Nephropathy-Patient-Pool-Analysis-768x390.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/IgA-Nephropathy-Patient-Pool-Analysis-1536x781.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/IgA-Nephropathy-Patient-Pool-Analysis.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>The clinical goal is therefore clear: lower proteinuria early, keep it down, and protect long-term kidney function. Even with a growing menu of IgA nephropathy medications, many patients still show persistent proteinuria despite supportive care, which is exactly why the field keeps looking for new mechanisms.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ultomiris-moa-why-blocking-c5-makes-sense-in-igan\"><span class=\"ez-toc-section\" id=\"ULTOMIRIS_MoA_Why_Blocking_C5_Makes_Sense_in_IgAN\"><\/span><strong>ULTOMIRIS MoA: Why Blocking C5 Makes Sense in IgAN<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>To understand why a drug built for rare blood and neuromuscular disorders now has a place in nephrology, it helps to look at the ULTOMIRIS MoA. Ravulizumab is a long-acting monoclonal antibody that binds complement component C5 and prevents its cleavage into C5a and C5b. That single step sits at the very end of the complement cascade, where all three activation routes converge. Blocking it has two downstream consequences:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>It stops formation of the membrane attack complex (C5b-9), a structure that can injure cells.<\/li>\n\n\n\n<li>It reduces generation of C5a, a potent pro-inflammatory signal that recruits and activates immune cells.<\/li>\n<\/ul>\n\n\n\n<p>In IgAN, complement activation is thought to be part of the injury loop. Galactose-deficient IgA1 and associated immune complexes deposit in the glomeruli, and complement components are frequently found alongside them in kidney biopsies. The prevailing hypothesis is that this deposition can activate complement and amplify local inflammation, driving damage to the filtration barrier and, in turn, proteinuria. By inhibiting terminal complement at C5, ULTOMIRIS targets a pathway implicated in IgAN-associated inflammation, with the goal of dampening that downstream injury.<\/p>\n\n\n\n<p><em>As Richard Lafayette, MD, of the Stanford Glomerular Disease Center and I CAN external scientific committee co-chair, put it, the approval gives physicians a C5 inhibitor that delivers sustained terminal complement inhibition, targeting a central driver of kidney inflammation. The Phase III findings build on earlier Phase II SANCTUARY data that first supported the concept in IgAN.<\/em><\/p>\n\n\n\n<p>It is worth being measured here. The proteinuria data show that terminal complement blockade can lower a key marker of kidney injury; whether it changes the long-term trajectory of kidney function is precisely what the ongoing I CAN trial is designed to answer.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-new-landscape-of-iga-nephropathy-treatments\"><span class=\"ez-toc-section\" id=\"The_New_Landscape_of_IgA_Nephropathy_Treatments\"><\/span><strong>The New Landscape of IgA Nephropathy Treatments<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The arrival of ULTOMIRIS comes at a time when the <a href=\"https:\/\/www.delveinsight.com\/blog\/iga-nephropathy-treatment-landscape\">IgA nephropathy treatment landscape<\/a> has undergone a significant transformation. As of August 2026, the National Kidney Foundation reported six FDA-approved therapies for IgAN, marking a major shift from an earlier treatment paradigm that relied primarily on supportive care and off-label corticosteroids. The current IgA nephropathy drugs market encompasses several therapies with distinct mechanisms of action, including Tarpeyo (budesonide), a delayed-release, targeted corticosteroid formulation that acts in the gut to reduce the immune activity responsible for producing abnormal IgA and is approved for a defined, time-limited treatment course to limit the risks associated with prolonged steroid exposure.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"339\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/ULTOMIRIS-Approval-Timeline-in-the-US-1024x339.webp\" alt=\"ULTOMIRIS-Approval-Timeline-in-the-US\" class=\"wp-image-36383\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/ULTOMIRIS-Approval-Timeline-in-the-US-1024x339.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/ULTOMIRIS-Approval-Timeline-in-the-US-300x99.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/ULTOMIRIS-Approval-Timeline-in-the-US-150x50.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/ULTOMIRIS-Approval-Timeline-in-the-US-768x254.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/ULTOMIRIS-Approval-Timeline-in-the-US-1536x509.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/ULTOMIRIS-Approval-Timeline-in-the-US.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/blog\/filspari-for-iga-nephropathy\"><strong>FILSPARI (sparsentan)<\/strong><\/a>, developed by <strong>Travere Therapeutics<\/strong>, is a dual endothelin and angiotensin II receptor antagonist supported by evidence of its effects on proteinuria and kidney function and distributed under a Risk Evaluation and Mitigation Strategy (REMS). <strong>FABHALTA (iptacopan)<\/strong>, developed by <strong>Novartis<\/strong>, is an oral complement inhibitor that targets Factor B in the alternative complement pathway and received accelerated FDA approval for IgAN in August 2024. Novartis also markets <strong>VANRAFIA (atrasentan)<\/strong>, an endothelin receptor antagonist that received accelerated approval in August 2025. Another addition to the treatment landscape is <strong>TRUTAKNA (atacicept)<\/strong>, a B-cell-directed therapy administered once weekly using an autoinjector, which received accelerated approval in July 2026.&nbsp;<\/p>\n\n\n\n<p>Collectively, these developments reflect a broader shift toward targeted, mechanism-based treatment approaches, with nephrologists increasingly incorporating newer therapies earlier in the treatment pathway. Market analysts anticipate further FDA decisions on <a href=\"https:\/\/www.delveinsight.com\/blog\/4-late-stage-iga-nephropathy-treatment-drugs\">IgAN drug candidates<\/a> before the end of 2026, suggesting that the evolving landscape of new IgA nephropathy treatments in 2026 will continue to expand.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-c5-vs-factor-b-two-complement-strategies-two-different-targets\"><span class=\"ez-toc-section\" id=\"C5_vs_Factor_B_Two_Complement_Strategies_Two_Different_Targets\"><\/span><strong>C5 vs. Factor B: Two Complement Strategies, Two Different Targets<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Although ULTOMIRIS and FABHALTA are both complement inhibitors, they target different points in the complement cascade. FABHALTA (iptacopan) is an oral inhibitor of complement Factor B, a proximal component of the alternative pathway, acting upstream at the level of the C3 and C5 convertases. In contrast, ULTOMIRIS (ravulizumab) is an intravenous monoclonal antibody that targets C5, acting downstream at the terminal complement stage shared by all activation pathways. These differences also translate into distinct administration profiles, with <a href=\"https:\/\/www.delveinsight.com\/blog\/fabhalta-for-igan-treatment\">Novartis\u2019 FABHALTA<\/a> taken orally at home and ULTOMIRIS administered through an intravenous infusion every eight weeks following a loading dose. The suitability of either treatment for an individual patient depends on clinical considerations, including disease characteristics, comorbidities, treatment access and patient preferences.<\/p>\n\n\n\n<p>However, these mechanistic and administration differences should not be interpreted as evidence of superior or inferior efficacy. The clinical development programs for the two therapies involved different trials, patient populations, and study designs, and no head-to-head study has directly compared them. Accordingly, no conclusions regarding their relative efficacy can be drawn. Instead, ULTOMIRIS introduces a C5-targeting approach to the treatment of immunoglobulin A nephropathy (IgAN), expanding the available options within the complement-inhibition class rather than replacing existing therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-conclusion-nbsp\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The FDA&#8217;s accelerated approval of ULTOMIRIS marks a notable step for IgAN: the drug&#8217;s fifth rare disease indication in the United States and the first and only C5 complement inhibitor approved to reduce proteinuria in adults with primary IgAN at risk of progression. The Phase III I CAN interim analysis showed a 46.6% reduction in 24-hour UPCR from baseline at Week 34 with ULTOMIRIS versus 5.6% with placebo, a placebo-adjusted effect of 43.4%, with reductions visible as early as Week 10 and sustained through Week 34.<\/p>\n\n\n\n<p>What remains to be proven is the long-term kidney benefit, and the Week 106 eGFR results will carry that weight. In the meantime, the ULTOMIRIS MoA adds a new, biologically grounded approach to the toolkit of <a href=\"https:\/\/www.delveinsight.com\/report-store\/iga-nephropathy-igan-market\">IgA nephropathy treatments<\/a>, expanding choice for patients and clinicians in a field that has never moved faster. For market watchers, the story to follow is how this latest entrant, and the broader wave of IgA nephropathy drugs, reshape care and the IgA nephropathy drugs market through 2026 and beyond.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/iga-nephropathy-igan-market\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/IgA-Nephropathy-Market-Analysis-1024x194.webp\" alt=\"IgA Nephropathy Market Analysis\" class=\"wp-image-36381\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/IgA-Nephropathy-Market-Analysis-1024x194.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/IgA-Nephropathy-Market-Analysis-300x57.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/IgA-Nephropathy-Market-Analysis-150x28.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/IgA-Nephropathy-Market-Analysis-768x145.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/IgA-Nephropathy-Market-Analysis-1536x291.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/IgA-Nephropathy-Market-Analysis.webp 1584w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Summary For years, people living with IgA nephropathy (IgAN) had very little to hold onto beyond blood pressure control and supportive care. In 2026, that picture looks dramatically different. On October 21, 2026, the US Food and Drug Administration (FDA) granted accelerated approval to AstraZeneca&#8217;s ULTOMIRIS (ravulizumab-cwvz) to reduce proteinuria in adults with primary IgAN [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":36379,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[18841,18839,18840,18877,22206,22235,19057],"industry":[17225],"therapeutic_areas":[17230],"class_list":["post-36376","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-iga-nephropathy","tag-iga-nephropathy-drug-pipeline","tag-iga-nephropathy-epidemiology","tag-iga-nephropathy-pipeline","tag-igan","tag-igan-treatment","tag-ultomiris","industry-pharmaceutical","therapeutic_areas-genito-urinary-system-and-sex-hormones"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.9 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>ULTOMIRIS Enters the IgA Nephropathy Drugs Space<\/title>\n<meta name=\"description\" content=\"FDA granted accelerated approval to AstraZeneca\u2019s ULTOMIRIS, to reduce proteinuria in adults with primary IgAN at risk of progression.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/ultomiris-for-igan-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ULTOMIRIS Enters the IgA Nephropathy Drugs Space\" \/>\n<meta property=\"og:description\" content=\"FDA granted accelerated approval to AstraZeneca\u2019s ULTOMIRIS, to reduce proteinuria in adults with primary IgAN at risk of progression.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/ultomiris-for-igan-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-02T12:04:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/ultomiris-for-igan-treatment.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ULTOMIRIS Enters the IgA Nephropathy Drugs Space","description":"FDA granted accelerated approval to AstraZeneca\u2019s ULTOMIRIS, to reduce proteinuria in adults with primary IgAN at risk of progression.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/ultomiris-for-igan-treatment","og_locale":"en_US","og_type":"article","og_title":"ULTOMIRIS Enters the IgA Nephropathy Drugs Space","og_description":"FDA granted accelerated approval to AstraZeneca\u2019s ULTOMIRIS, to reduce proteinuria in adults with primary IgAN at risk of progression.","og_url":"https:\/\/www.delveinsight.com\/blog\/ultomiris-for-igan-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-11-02T12:04:00+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/ultomiris-for-igan-treatment.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.delveinsight.com\/blog\/ultomiris-for-igan-treatment#article","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/ultomiris-for-igan-treatment"},"author":{"name":"Sandeep Joshi","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"headline":"AstraZeneca\u2019s ULTOMIRIS: The First C5 Inhibitor Enters the Race to Tame Proteinuria in IgA Nephropathy","datePublished":"2026-11-02T12:04:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/ultomiris-for-igan-treatment"},"wordCount":1687,"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/ultomiris-for-igan-treatment#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/ultomiris-for-igan-treatment.webp","keywords":["IgA Nephropathy","IgA Nephropathy Drug Pipeline","IgA Nephropathy Epidemiology","IgA Nephropathy Pipeline","IgAN","IgAN treatment","Ultomiris"],"articleSection":["Articles"],"inLanguage":"en-US","copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/www.delveinsight.com\/blog\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/ultomiris-for-igan-treatment","url":"https:\/\/www.delveinsight.com\/blog\/ultomiris-for-igan-treatment","name":"ULTOMIRIS Enters the IgA Nephropathy Drugs Space","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/ultomiris-for-igan-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/ultomiris-for-igan-treatment#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/ultomiris-for-igan-treatment.webp","datePublished":"2026-11-02T12:04:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"FDA granted accelerated approval to AstraZeneca\u2019s ULTOMIRIS, to reduce proteinuria in adults with primary IgAN at risk of progression.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/ultomiris-for-igan-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/ultomiris-for-igan-treatment#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/ultomiris-for-igan-treatment.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/ultomiris-for-igan-treatment.webp","width":466,"height":284,"caption":"ultomiris-for-igan-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/11\/ultomiris-for-igan-treatment-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">IgA Nephropathy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">IgA Nephropathy Drug Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">IgA Nephropathy Epidemiology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">IgA Nephropathy Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">IgAN<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">IgAN treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Ultomiris<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">IgA Nephropathy<\/span>","<span class=\"advgb-post-tax-term\">IgA Nephropathy Drug Pipeline<\/span>","<span class=\"advgb-post-tax-term\">IgA Nephropathy Epidemiology<\/span>","<span class=\"advgb-post-tax-term\">IgA Nephropathy Pipeline<\/span>","<span class=\"advgb-post-tax-term\">IgAN<\/span>","<span class=\"advgb-post-tax-term\">IgAN treatment<\/span>","<span class=\"advgb-post-tax-term\">Ultomiris<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 hours ago","modified":"Updated 4 hours ago"},"absolute_dates":{"created":"Posted on Nov 2, 2026","modified":"Updated on Nov 2, 2026"},"absolute_dates_time":{"created":"Posted on Nov 2, 2026 5:34 pm","modified":"Updated on Nov 2, 2026 4:35 pm"},"featured_img_caption":"ultomiris-for-igan-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36376","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=36376"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36376\/revisions"}],"predecessor-version":[{"id":36384,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/36376\/revisions\/36384"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/36379"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=36376"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=36376"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=36376"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=36376"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=36376"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}